摘要 ： 厦门大学林树海教授与合作者共同推出首个快速、平台无依赖的反向脂质组学质谱AI模型LipidIN，显著提升脂质组鉴定速度 与深度实现跨平台标准化分析。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 基因、蛋白、糖和脂质是生命体构成的四大类重要分子物质。其中，脂质扮演着无可替代的关键角色。它们不仅是细胞 膜的"建筑骨架"与能量的"储备仓库"，更是调控生命活动的"信号使者"。因此，脂质组学能够精准揭示"正在或已经 发生"的生命活动现象，其代谢异常与心脑血管疾病、肿瘤、糖尿病等重大疾病息息相关， 然而，脂质分子的世界充满了精微而复杂的变奏。仅仅是碳链长度、双键位置、极性头基的微小差异，就足以创造出庞 大的分子家族，这种高度的异质性在系统性研究面前构筑了一道难以逾越的技术鸿沟。尽管LC–MS已成为定量脂质组 学的主流技术，但其 在注释准确性、数据库覆盖度、搜库效率以及深度结构解析能力上仍难以满足研究者的解析需求 。 点击免费限量礼盒 在 这 一 背 景 下 ， 厦 门 大 学 林 树 海 团 队 及 合 作 者 近 日 在 Nature ...

Summary of Bruker (BRKR) 2025 Conference Call Company Overview - **Company**: Bruker Corporation (BRKR) - **Event**: 2025 Conference Call held on June 04, 2025 Key Industry Insights - **Industry**: Mass Spectrometry and Proteomics - **Market Trends**: The mass spectrometry market is experiencing significant innovation, particularly in proteomics and metabolomics, with a focus on high sensitivity and throughput solutions [3][10][12] Core Product Innovations 1. **TIMS Ultra and AIP**: - New product launched to enhance MSMS sensitivity and bandwidth, allowing for more peptides and proteins to be analyzed [5][7] - Significant advancements in single-cell proteomics, enabling analysis of smaller cells than previously possible [8] 2. **TIMS Metabo Instrument**: - Aimed at the high-resolution accurate mass market for small molecules, targeting applications in PFAS research, toxicology, and metabolomics [11][12] - Expected to double the market opportunity for Bruker, potentially reaching a $200 million market share [15] 3. **TIMS Omni**: - A revolutionary mass spectrometer combining TIMS technology with Omni Trap, enabling top-down proteomics and functional proteomics [17][18] - Positioned to create a new category in mass spectrometry with no direct competition [19] Financial Outlook - **Revenue Guidance**: Anticipated moderate growth in 2026, with expectations of organic growth between 6% to 8% [32] - **Cost Management**: Bruker is implementing cost-cutting measures, including reducing operational costs in European sites and optimizing R&D spending [33][35] Market Dynamics - **Academic Market**: Anticipated decline in academic spending by 20-25% due to budget constraints, impacting overall revenue [22][30] - **Defense and Homeland Security**: Notable growth in the detection business for radiological and chemical threats, with potential revenue increases of $20 million next year [38][39] Emerging Markets and Opportunities - **Semiconductor and AI**: Strong demand in metrology for high-performance computing and AI applications, expected to grow from 8% to potentially 12% of total revenue [45][46] - **China Market**: Potential for stimulus-driven growth in high-end research tools, although timing remains uncertain [51][52] Strategic Developments - **Cell Analysis and Diagnostics**: Launch of a new benchtop product aimed at broadening market access for antibody discovery and cell line selection [54][55] - **Spatial Biology**: Continued investment in spatial biology technologies, enhancing capabilities in multi-omics and improving throughput and detection efficiency [61][62] Conclusion - Bruker is positioned for growth through innovative product offerings in mass spectrometry and proteomics, despite facing challenges in academic funding and market uncertainties. The company is strategically focusing on high-growth areas such as biopharma, diagnostics, and advanced manufacturing technologies.